Championing experimental digital art incubator Onassis ONX heads downtown to christen its new Tribeca home with TECHNE: ...

Techne Corporation, the Minneapolis-based biotechnology company that now does business under the “Bio-Techne” brand, recently announced that it’s investing $10 million CyVek, Inc.—and it might ...

This was the stock's second consecutive day of gains.

Bio-Techne (NASDAQ: TECH) announced the $60 million acquisition of Novus Biologicals earlier this month and the $300 million acquisition of ProteinSimple in June. When asked if industry consolidation ...

The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Bio-Techne Corp. closed 13.72% short of its 52-week high of $79.28, which the company achieved on February 5th.

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...

More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...